Trials / Conditions / T Acute Lymphoblastic Leukemia

T Acute Lymphoblastic Leukemia

20 registered clinical trials studyying T Acute Lymphoblastic Leukemia — 8 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphobl NCT07072585	Children's Oncology Group	Phase 2 / Phase 3
Recruiting	Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plu NCT06738368	University of Washington	Phase 2
Not Yet Recruiting	Efficacy and Safety of CD7 CAR-T in Newly Diagnosed High-Risk T-LBL/ALL NCT07476027	Institute of Hematology & Blood Diseases Hospital, China	EARLY_Phase 1
Recruiting	Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations NCT07012447	yuejun Liu	Phase 2
Recruiting	Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-ALL NCT06633354	Zhejiang University	EARLY_Phase 1
Withdrawn	Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemi NCT06210750	National Cancer Institute (NCI)	Phase 2
Recruiting	Use of a New Medicine "Daratumumab" to Treat Left-over Cancer in a Blood Cancer Called "T Acute Lymphoblastic NCT07021677	Tata Memorial Centre	Phase 2
Recruiting	Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma NCT05602194	Children's Oncology Group	Phase 3
Unknown	Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL NCT04582487	Gruppo Italiano Malattie EMatologiche dell'Adulto	N/A
Unknown	RD13-01 for Patients With r/r CD7+ T-ALL/T-LBL NCT04620655	Min Xiang	N/A
Active Not Recruiting	Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting NCT04128501	M.D. Anderson Cancer Center	Phase 2
Unknown	Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies NCT05127135	Fundamenta Therapeutics, Ltd.	Phase 1
Withdrawn	Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase NCT02538926	University of Washington	Phase 2
Terminated	EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acu NCT03519984	University of Southern California	Phase 1
Active Not Recruiting	Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromoso NCT03007147	Children's Oncology Group	Phase 3
Completed	Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia NCT02484430	National Cancer Institute (NCI)	Phase 2
Terminated	Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia NCT02767934	University of Washington	Phase 2
Terminated	BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma NCT02763384	Washington University School of Medicine	Phase 2
Recruiting	Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymph NCT00501826	M.D. Anderson Cancer Center	Phase 2
Completed	Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia o NCT00408005	National Cancer Institute (NCI)	Phase 3